AR075428A1 - Formulacion de doramectina en dosis elevada - Google Patents
Formulacion de doramectina en dosis elevadaInfo
- Publication number
- AR075428A1 AR075428A1 ARP100100431A ARP100100431A AR075428A1 AR 075428 A1 AR075428 A1 AR 075428A1 AR P100100431 A ARP100100431 A AR P100100431A AR P100100431 A ARP100100431 A AR P100100431A AR 075428 A1 AR075428 A1 AR 075428A1
- Authority
- AR
- Argentina
- Prior art keywords
- vitamin
- fat
- group
- antiparasitic
- veterinary
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
- 239000003096 antiparasitic agent Substances 0.000 abstract 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 abstract 4
- 229930003231 vitamin Natural products 0.000 abstract 4
- 239000011782 vitamin Substances 0.000 abstract 4
- 229940088594 vitamin Drugs 0.000 abstract 4
- 235000013343 vitamin Nutrition 0.000 abstract 4
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 2
- 229920000742 Cotton Polymers 0.000 abstract 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 2
- 229930003316 Vitamin D Natural products 0.000 abstract 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 2
- 229930003427 Vitamin E Natural products 0.000 abstract 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 2
- 230000002141 anti-parasite Effects 0.000 abstract 2
- 229940125687 antiparasitic agent Drugs 0.000 abstract 2
- 229960002903 benzyl benzoate Drugs 0.000 abstract 2
- 229960003997 doramectin Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 235000019155 vitamin A Nutrition 0.000 abstract 2
- 239000011719 vitamin A Substances 0.000 abstract 2
- 235000019166 vitamin D Nutrition 0.000 abstract 2
- 239000011710 vitamin D Substances 0.000 abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
- 235000019165 vitamin E Nutrition 0.000 abstract 2
- 229940046009 vitamin E Drugs 0.000 abstract 2
- 239000011709 vitamin E Substances 0.000 abstract 2
- 229940045997 vitamin a Drugs 0.000 abstract 2
- 229940046008 vitamin d Drugs 0.000 abstract 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 abstract 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 abstract 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 abstract 1
- 239000005660 Abamectin Substances 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 229950008167 abamectin Drugs 0.000 abstract 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 abstract 1
- 229960002346 eprinomectin Drugs 0.000 abstract 1
- 229960002418 ivermectin Drugs 0.000 abstract 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 abstract 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 abstract 1
- 229960004816 moxidectin Drugs 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Composicion veterinaria antiparasitaria que comprende a) doramectina al 3-6% p/v, b) aceite de algodon al 39-60% v/v, c) benzoato de bencilo al 30-50% v/v; y opcionalmente d) uno o más entre conservante, excipiente auxiliar y vitamina liposoluble. Reivindicacion 4: Composicion segun la reivindicacion 3, que comprende adicionalmente una o más vitaminas liposolubles seleccionadas del grupo que consiste en vitamina A, vitamina D y vitamina E. Reivindicacion 8: Utilizacion de la composicion segun una cualquiera de las reivindicaciones 1 a 7 para preparar un medicamento para la prevencion, tratamiento o control de parásitos en el ganado, que comprende la administracion por vía parenteral de dicho medicamento a dicho animal. Reivindicacion 10: Composicion veterinaria politerápica antiparasitaria que comprende a) doramectina al 1-3% p/v, b) agente antiparasitario al 1-3% p/v o combinacion al 1-3% p/v de más de un agente antiparasitario seleccionado del grupo que consiste en abamectina, ivermectina, eprinomectina, moxidectina y milbemicina, c) aceite de algodon al 39-75% v/v, d) benzoato de bencilo al 25-50% v/v; y opcionalmente e) uno o más entre un conservante, excipiente auxiliar y vitamina liposoluble, en la que dicha vitamina se selecciona del grupo que consiste en vitamina A, vitamina D y vitamina E.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15291109P | 2009-02-16 | 2009-02-16 | |
| US21983709P | 2009-06-24 | 2009-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075428A1 true AR075428A1 (es) | 2011-03-30 |
Family
ID=42060687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100431A AR075428A1 (es) | 2009-02-16 | 2010-02-15 | Formulacion de doramectina en dosis elevada |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8551962B2 (es) |
| EP (1) | EP2396006B1 (es) |
| JP (1) | JP2012517994A (es) |
| KR (1) | KR101326428B1 (es) |
| CN (1) | CN102316876B (es) |
| AR (1) | AR075428A1 (es) |
| AU (1) | AU2010233409B2 (es) |
| BR (1) | BRPI1008822B1 (es) |
| CA (1) | CA2750626C (es) |
| CL (1) | CL2011001775A1 (es) |
| CO (1) | CO6410307A2 (es) |
| DK (1) | DK2396006T3 (es) |
| ES (1) | ES2399228T3 (es) |
| MX (1) | MX2011008614A (es) |
| NZ (1) | NZ594389A (es) |
| PL (1) | PL2396006T3 (es) |
| PT (1) | PT2396006E (es) |
| WO (1) | WO2010116267A1 (es) |
| ZA (1) | ZA201105310B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013137748A1 (en) * | 2012-03-13 | 2013-09-19 | Bayer New Zealand Limited | Long acting compositions |
| ES2436249B1 (es) * | 2012-06-25 | 2014-06-23 | Javier Alberto ALONSO-VAQUERO VELASCO | Composición antiparasitaria para el control y tratamiento de parásitos de diferentes especies animales, caracterizada por combinar Moxidectina con las vitaminas: A, D3, y E |
| WO2014098623A1 (en) * | 2012-12-20 | 2014-06-26 | Alleva Animal Health Limited | Injectable eprinomectin formulation and anthelmintic use thereof |
| CN103977017B (zh) * | 2014-06-03 | 2016-09-07 | 重庆布尔动物药业有限公司 | 一种兽用抗寄生虫注射液及其制备方法 |
| WO2025024908A1 (en) * | 2023-07-28 | 2025-02-06 | Elanco Saude Animal Ltda | Antiparasitic compositions of macrocyclic lactones |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8800986A1 (es) | 1985-07-27 | 1987-12-01 | Pfizer | Un procedimiento para la produccion de un nuevo derivado de avermectina |
| DK0393890T3 (da) * | 1989-04-11 | 1992-09-28 | Pfizer | Injicerbart præparat indeholdende 25-cyclohexyl-avermectin B1 |
| US6001822A (en) | 1989-04-11 | 1999-12-14 | Pfizer Inc. | Antiparasitic formulations |
| KR100277287B1 (ko) * | 1995-09-25 | 2001-01-15 | 맨슨 하비 콜린 | 거대환 락톤 구충제 조성물 |
| DE19613972A1 (de) | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
| AU728221B2 (en) | 1996-06-05 | 2001-01-04 | Ashmont Holdings Limited | Injectable compositions |
| DE19638045A1 (de) | 1996-09-18 | 1998-03-19 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen |
| US6174540B1 (en) | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
| KR20000025762A (ko) * | 1998-10-14 | 2000-05-06 | 유충식 | 이버멕틴류의 가용화 조성물 |
| GB9825402D0 (en) * | 1998-11-19 | 1999-01-13 | Pfizer Ltd | Antiparasitic formulations |
| GB9827727D0 (en) | 1998-12-16 | 1999-02-10 | Pfizer Ltd | Antiparasitic formulations |
| CN1304727A (zh) * | 2000-10-20 | 2001-07-25 | 王玉万 | 一种以苯甲酸苄酯或氮酮为助溶剂的含阿维菌素或伊维菌素的注射液 |
-
2010
- 2010-02-02 CN CN2010800079297A patent/CN102316876B/zh active Active
- 2010-02-02 BR BRPI1008822-9A patent/BRPI1008822B1/pt active IP Right Grant
- 2010-02-02 NZ NZ594389A patent/NZ594389A/xx not_active IP Right Cessation
- 2010-02-02 JP JP2011549707A patent/JP2012517994A/ja active Pending
- 2010-02-02 KR KR1020117021507A patent/KR101326428B1/ko not_active Expired - Fee Related
- 2010-02-02 DK DK10703519.8T patent/DK2396006T3/da active
- 2010-02-02 PL PL10703519T patent/PL2396006T3/pl unknown
- 2010-02-02 AU AU2010233409A patent/AU2010233409B2/en active Active
- 2010-02-02 PT PT107035198T patent/PT2396006E/pt unknown
- 2010-02-02 MX MX2011008614A patent/MX2011008614A/es active IP Right Grant
- 2010-02-02 WO PCT/IB2010/050443 patent/WO2010116267A1/en not_active Ceased
- 2010-02-02 EP EP10703519A patent/EP2396006B1/en not_active Not-in-force
- 2010-02-02 CA CA2750626A patent/CA2750626C/en not_active Expired - Fee Related
- 2010-02-02 ES ES10703519T patent/ES2399228T3/es active Active
- 2010-02-02 US US13/147,600 patent/US8551962B2/en not_active Expired - Fee Related
- 2010-02-15 AR ARP100100431A patent/AR075428A1/es active IP Right Grant
-
2011
- 2011-07-19 ZA ZA2011/05310A patent/ZA201105310B/en unknown
- 2011-07-21 CL CL2011001775A patent/CL2011001775A1/es unknown
- 2011-08-30 CO CO11111108A patent/CO6410307A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2011001775A1 (es) | 2011-10-28 |
| MX2011008614A (es) | 2011-09-09 |
| EP2396006B1 (en) | 2012-12-19 |
| EP2396006A1 (en) | 2011-12-21 |
| PT2396006E (pt) | 2013-02-13 |
| AU2010233409A1 (en) | 2011-08-11 |
| NZ594389A (en) | 2012-09-28 |
| CA2750626C (en) | 2013-10-01 |
| US8551962B2 (en) | 2013-10-08 |
| ZA201105310B (en) | 2012-09-26 |
| US20110294751A1 (en) | 2011-12-01 |
| KR101326428B1 (ko) | 2013-11-20 |
| WO2010116267A1 (en) | 2010-10-14 |
| ES2399228T3 (es) | 2013-03-26 |
| DK2396006T3 (da) | 2013-02-11 |
| BRPI1008822B1 (pt) | 2019-04-09 |
| KR20110116231A (ko) | 2011-10-25 |
| AU2010233409B2 (en) | 2012-05-17 |
| CN102316876B (zh) | 2013-07-17 |
| PL2396006T3 (pl) | 2013-06-28 |
| HK1161087A1 (en) | 2012-08-24 |
| CO6410307A2 (es) | 2012-03-30 |
| JP2012517994A (ja) | 2012-08-09 |
| CN102316876A (zh) | 2012-01-11 |
| BRPI1008822A2 (pt) | 2016-03-08 |
| CA2750626A1 (en) | 2010-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000739A1 (es) | Agente prolongado de control de ectoparasito para animales. | |
| MX2024004921A (es) | Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos. | |
| MX2016015326A (es) | Combinacion, composicion y metodo de administracion de la combinacion o composicion a animales. | |
| BR112017021073A2 (pt) | composições injetáveis de liberação prolongada compreendendo um agente ativo de isoxazolina, seus métodos e usos | |
| CR7140A (es) | Antranilamidas con una cadena colateral de un heteroarylsulfonil, metodos para la produccion de los mismos, su uso como medicamento o agente diagnostico y preparaciones farmaceuticas contenidas en dichos compuestos | |
| AR075428A1 (es) | Formulacion de doramectina en dosis elevada | |
| BR112014019262A8 (pt) | Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas | |
| AR103803A1 (es) | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| ES2723779T3 (es) | Formulación para el control de piojos y garrapatas en el ganado | |
| UY28271A1 (es) | Compuestos químicos | |
| UY38965A (es) | Composiciones que comprenden canabidiol y flavanonas | |
| AR078860A1 (es) | Asociaciones farmaceuticas, composiciones farmaceuticas, medicamento y metodo para el tratamiento de animales | |
| AR122059A1 (es) | Usos y formulaciones de cannabinoides | |
| MX2024006251A (es) | Compuesto quimerico para la degradacion dirigida de la proteina del receptor de androgenos, metodo de preparacion y uso medico del mismo. | |
| AR043824A1 (es) | Composiciones y metodo para tratar las infecciones microbianas y parasitarias en el ganado y otros animales | |
| RU2017138118A (ru) | Комбинации противоглистных агентов и способы их применения | |
| MX2019015927A (es) | Composiciones para administración de fármacos y métodos de uso de las mismas. | |
| MX389554B (es) | Formulaciones antihelminticas veterinarias estables. | |
| AR057319A1 (es) | Composicion para la administracion topica y metodo para evitar o tratar infeccion o infestacion endoparasitica y ectoparasitica en un animal de sangre caliente | |
| AR081970A1 (es) | Formulacion inyectable de una lactona macrociclica y levamisol, formulacion y uso veterinario | |
| PE20151726A1 (es) | Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles | |
| Zapa et al. | Toltrazuril+ fenbendazole for cattle: Pharmacokinetics and efficacy against Eimeria spp. and gastrointestinal nematodes | |
| EP1968585B1 (en) | Veterinarian composition for use as fasciolicide in animals | |
| GT200900295A (es) | Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |